EA028060B1 - Комбинированная терапия бокового амиотрофического склероза - Google Patents
Комбинированная терапия бокового амиотрофического склероза Download PDFInfo
- Publication number
- EA028060B1 EA028060B1 EA201490011A EA201490011A EA028060B1 EA 028060 B1 EA028060 B1 EA 028060B1 EA 201490011 A EA201490011 A EA 201490011A EA 201490011 A EA201490011 A EA 201490011A EA 028060 B1 EA028060 B1 EA 028060B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- riluzole
- administered
- therapeutically effective
- effective amount
- individual
- Prior art date
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title claims abstract description 26
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 229960004181 riluzole Drugs 0.000 claims abstract description 168
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims abstract description 167
- 238000000034 method Methods 0.000 claims abstract description 55
- 230000001965 increasing effect Effects 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 230000002411 adverse Effects 0.000 abstract description 8
- 230000003247 decreasing effect Effects 0.000 abstract description 3
- 239000000902 placebo Substances 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 12
- 230000036470 plasma concentration Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000004448 titration Methods 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- 238000011260 co-administration Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- -1 for example Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010049565 Muscle fatigue Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 description 1
- LAQJGAKLLZAETL-UHFFFAOYSA-N 2h-pyrazin-3-one Chemical compound O=C1CN=CC=N1 LAQJGAKLLZAETL-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000442132 Lactarius lactarius Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 101150034381 Slc27a5 gene Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- QVZZPLDJERFENQ-NKTUOASPSA-N bassianolide Chemical compound CC(C)C[C@@H]1N(C)C(=O)[C@@H](C(C)C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C(C)C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C(C)C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C(C)C)OC1=O QVZZPLDJERFENQ-NKTUOASPSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003642 nicergoline Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- UPCXAARSWVHVLY-UHFFFAOYSA-N tris(2-hydroxyethyl)azanium;acetate Chemical compound CC(O)=O.OCCN(CCO)CCO UPCXAARSWVHVLY-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161507381P | 2011-07-13 | 2011-07-13 | |
| US61/507,381 | 2011-07-13 | ||
| US201161544533P | 2011-10-07 | 2011-10-07 | |
| US61/544,533 | 2011-10-07 | ||
| US201261637759P | 2012-04-24 | 2012-04-24 | |
| US201261637770P | 2012-04-24 | 2012-04-24 | |
| US61/637,770 | 2012-04-24 | ||
| US61/637,759 | 2012-04-24 | ||
| US201261646699P | 2012-05-14 | 2012-05-14 | |
| US61/646,699 | 2012-05-14 | ||
| PCT/US2012/046523 WO2013010015A2 (en) | 2011-07-13 | 2012-07-12 | Combination als therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201490011A1 EA201490011A1 (ru) | 2014-08-29 |
| EA028060B1 true EA028060B1 (ru) | 2017-10-31 |
Family
ID=47506929
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201490011A EA028060B1 (ru) | 2011-07-13 | 2012-07-12 | Комбинированная терапия бокового амиотрофического склероза |
| EA201791043A EA201791043A1 (ru) | 2011-07-13 | 2012-07-12 | Комбинированная терапия бокового амиотрофического склероза |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201791043A EA201791043A1 (ru) | 2011-07-13 | 2012-07-12 | Комбинированная терапия бокового амиотрофического склероза |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10272082B2 (https=) |
| EP (1) | EP2731611B1 (https=) |
| JP (2) | JP6145946B2 (https=) |
| KR (1) | KR101951220B1 (https=) |
| CN (2) | CN104039148A (https=) |
| AU (2) | AU2012281042B2 (https=) |
| BR (1) | BR112014000742A2 (https=) |
| CA (1) | CA2849213A1 (https=) |
| EA (2) | EA028060B1 (https=) |
| HK (1) | HK1197178A1 (https=) |
| IL (1) | IL230391B (https=) |
| IN (1) | IN2014DN00200A (https=) |
| PH (1) | PH12014500094A1 (https=) |
| SG (1) | SG10201605707UA (https=) |
| WO (1) | WO2013010015A2 (https=) |
| ZA (1) | ZA201400236B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| US20160263110A1 (en) * | 2013-11-04 | 2016-09-15 | Ab Science | Use of masitinib for treatment of amyotrophic lateral sclerosis |
| HUE057533T2 (hu) | 2014-04-29 | 2022-05-28 | Cytokinetics Inc | Eljárások vitálkapacitás csökkenésének gátlására |
| EA038518B1 (ru) * | 2014-11-21 | 2021-09-09 | Биохэйвен Фармасьютикал Холдинг Компани Лтд. | Сублингвальный препарат рилузола |
| MX2017006454A (es) * | 2014-11-21 | 2018-03-23 | Biohaven Pharm Holding Co Ltd | Administracion sublingual de riluzol. |
| EP3072513A1 (en) * | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| MX390495B (es) | 2016-03-25 | 2025-03-20 | Ab Science | Uso de masitinib para el tratamiento de una subpoblación de pacientes con esclerosis lateral amiotrófica. |
| WO2021055890A1 (en) * | 2019-09-20 | 2021-03-25 | Icahn School Of Medicine At Mount Sinai | Controlled release formulations of riluzole and their uses |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030083318A1 (en) * | 2001-10-25 | 2003-05-01 | Jean-Pierre Julien | Therapy for neurodegenerative diseases |
| US20040235801A1 (en) * | 2001-10-25 | 2004-11-25 | Jean-Pierre Julien | Therapy for stroke |
| US20090029345A1 (en) * | 2006-08-01 | 2009-01-29 | Alan Russell | Modulating skeletal muscle |
| US7598248B2 (en) * | 2006-08-02 | 2009-10-06 | Cytokinetics, Inc. | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use |
| US20110268729A1 (en) * | 2008-07-11 | 2011-11-03 | Bams Abila | Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
| BE788065A (fr) | 1971-08-26 | 1973-02-26 | Degussa | Nouvelles aza-benzimidazoles et procede pour leur preparation |
| IT1156732B (it) | 1978-05-10 | 1987-02-04 | Roussel Maestretti Spa | Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione |
| US4668686A (en) | 1985-04-25 | 1987-05-26 | Bristol-Myers Company | Imidazoquinoline antithrombrogenic cardiotonic agents |
| US4775674A (en) | 1986-05-23 | 1988-10-04 | Bristol-Myers Company | Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors |
| US4943573A (en) | 1989-11-01 | 1990-07-24 | Bristol-Myers Squibb Company | Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility |
| US5354759A (en) | 1991-09-12 | 1994-10-11 | Fujisawa Pharmaceutical Co., Ltd. | Angiotenin II antagonizing heterocyclic compounds |
| JPH0641135A (ja) | 1992-07-21 | 1994-02-15 | Nippon Soda Co Ltd | イミダゾプテリジン誘導体及びその製造方法 |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| CA2333770A1 (en) | 1998-06-04 | 1999-12-09 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| DE50015443D1 (de) | 1999-10-08 | 2008-12-18 | Gruenenthal Gmbh | Bicyclische imidazo-5-yl-aminderivate |
| HUP0203052A3 (en) | 1999-10-08 | 2004-06-28 | Gruenenthal Gmbh | Bicyclic imidazo-3-yl-amine derivatives, process for their preparation, pharmaceutical compositions containing them and their use |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| GB0212048D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| US20040166137A1 (en) | 2002-11-08 | 2004-08-26 | Lackey John William | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| CA2529196A1 (en) | 2003-06-26 | 2005-02-17 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
| EP1646614A4 (en) | 2003-07-01 | 2008-09-10 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
| US20050250794A1 (en) | 2003-12-19 | 2005-11-10 | Andrew Napper | Methods of treating a disorder |
| JP2007529422A (ja) | 2004-01-29 | 2007-10-25 | エリクシアー ファーマシューティカルズ， インコーポレイテッド | 抗ウイルス治療 |
| WO2005108374A1 (en) | 2004-04-29 | 2005-11-17 | Fmc Corporation | Insecticidal diazole and triazole derivatives |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006036883A2 (en) | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| CA2598489A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| WO2007125321A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| EP2037931A2 (en) | 2006-04-25 | 2009-03-25 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
| WO2008016648A2 (en) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| CN101522681B (zh) * | 2006-08-02 | 2012-10-03 | 赛特凯恩蒂克公司 | 特定的化学个体、组合物和方法 |
| ATE543819T1 (de) | 2006-10-19 | 2012-02-15 | Signal Pharm Llc | Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| WO2008075007A1 (en) | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
| MX2009007661A (es) | 2007-01-19 | 2009-12-14 | Ardea Biosciences Inc | Inhibidores de mek. |
| WO2008121333A1 (en) | 2007-03-30 | 2008-10-09 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
| EP2018854A1 (en) * | 2007-07-27 | 2009-01-28 | Merz Pharma GmbH & Co. KGaA | Novel combinations of neramexane for the treatment of neurodegenerative disorders |
| EP2244711A4 (en) | 2008-02-04 | 2011-08-24 | Cytokinetics Inc | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
| US7998976B2 (en) | 2008-02-04 | 2011-08-16 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| CA2744498C (en) | 2008-11-25 | 2017-10-24 | University Of Rochester | Mlk inhibitors and methods of use |
| EP2228054A1 (en) * | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| RU2012101792A (ru) | 2009-06-19 | 2013-07-27 | Нопп Ньюросайенсиз, Инк. | Композиции и способы для лечения бокового амиотрофического склероза |
| SG10201701101YA (en) | 2012-04-02 | 2017-04-27 | Cytokinetics Inc | Methods for improving diaphragm function |
| CN111840294A (zh) | 2012-04-11 | 2020-10-30 | 赛特凯恩蒂克公司 | 改善对骨骼肌疲劳的抵抗力的方法 |
| HUE057533T2 (hu) | 2014-04-29 | 2022-05-28 | Cytokinetics Inc | Eljárások vitálkapacitás csökkenésének gátlására |
-
2012
- 2012-07-12 KR KR1020147000783A patent/KR101951220B1/ko not_active Expired - Fee Related
- 2012-07-12 US US14/131,649 patent/US10272082B2/en not_active Expired - Fee Related
- 2012-07-12 BR BR112014000742A patent/BR112014000742A2/pt not_active Application Discontinuation
- 2012-07-12 AU AU2012281042A patent/AU2012281042B2/en not_active Ceased
- 2012-07-12 EP EP12811325.5A patent/EP2731611B1/en active Active
- 2012-07-12 WO PCT/US2012/046523 patent/WO2013010015A2/en not_active Ceased
- 2012-07-12 CA CA2849213A patent/CA2849213A1/en not_active Abandoned
- 2012-07-12 EA EA201490011A patent/EA028060B1/ru not_active IP Right Cessation
- 2012-07-12 SG SG10201605707UA patent/SG10201605707UA/en unknown
- 2012-07-12 HK HK14110537.3A patent/HK1197178A1/xx unknown
- 2012-07-12 JP JP2014520335A patent/JP6145946B2/ja not_active Expired - Fee Related
- 2012-07-12 CN CN201280034661.5A patent/CN104039148A/zh active Pending
- 2012-07-12 PH PH1/2014/500094A patent/PH12014500094A1/en unknown
- 2012-07-12 CN CN201811116043.0A patent/CN109316480A/zh active Pending
- 2012-07-12 EA EA201791043A patent/EA201791043A1/ru unknown
- 2012-07-12 IN IN200DEN2014 patent/IN2014DN00200A/en unknown
-
2014
- 2014-01-09 IL IL230391A patent/IL230391B/en active IP Right Grant
- 2014-01-10 ZA ZA2014/00236A patent/ZA201400236B/en unknown
-
2016
- 2016-10-13 AU AU2016244263A patent/AU2016244263A1/en not_active Abandoned
-
2017
- 2017-04-28 JP JP2017090313A patent/JP2017128610A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030083318A1 (en) * | 2001-10-25 | 2003-05-01 | Jean-Pierre Julien | Therapy for neurodegenerative diseases |
| US20040235801A1 (en) * | 2001-10-25 | 2004-11-25 | Jean-Pierre Julien | Therapy for stroke |
| US20090029345A1 (en) * | 2006-08-01 | 2009-01-29 | Alan Russell | Modulating skeletal muscle |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| US7598248B2 (en) * | 2006-08-02 | 2009-10-06 | Cytokinetics, Inc. | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use |
| US20110268729A1 (en) * | 2008-07-11 | 2011-11-03 | Bams Abila | Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist |
Also Published As
| Publication number | Publication date |
|---|---|
| US20140243344A1 (en) | 2014-08-28 |
| IN2014DN00200A (https=) | 2015-06-05 |
| EP2731611A4 (en) | 2015-02-18 |
| AU2012281042B2 (en) | 2016-07-14 |
| NZ619924A (en) | 2016-02-26 |
| JP2017128610A (ja) | 2017-07-27 |
| EP2731611A2 (en) | 2014-05-21 |
| WO2013010015A3 (en) | 2014-05-15 |
| EA201791043A1 (ru) | 2017-09-29 |
| WO2013010015A2 (en) | 2013-01-17 |
| CN104039148A (zh) | 2014-09-10 |
| IL230391B (en) | 2019-03-31 |
| BR112014000742A2 (pt) | 2016-08-23 |
| SG10201605707UA (en) | 2016-09-29 |
| CA2849213A1 (en) | 2013-01-17 |
| AU2012281042A1 (en) | 2014-01-30 |
| JP2014520856A (ja) | 2014-08-25 |
| KR101951220B1 (ko) | 2019-02-22 |
| JP6145946B2 (ja) | 2017-06-14 |
| KR20140074270A (ko) | 2014-06-17 |
| AU2016244263A1 (en) | 2016-11-03 |
| EA201490011A1 (ru) | 2014-08-29 |
| ZA201400236B (en) | 2014-10-29 |
| PH12014500094A1 (en) | 2014-03-17 |
| HK1197178A1 (en) | 2015-01-09 |
| EP2731611B1 (en) | 2019-09-18 |
| US10272082B2 (en) | 2019-04-30 |
| CN109316480A (zh) | 2019-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7650929B2 (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| EA028060B1 (ru) | Комбинированная терапия бокового амиотрофического склероза | |
| EP3265087B1 (en) | Method of treatment with tradipitant | |
| JP2013505983A5 (https=) | ||
| EP4114466B1 (en) | Treatment of pain and vasoconstriction | |
| AU2012321110A1 (en) | Combination treatment | |
| RU2012117563A (ru) | Режим дозирования модулятора рецептора s1p | |
| JP6137833B2 (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| WO2019222564A1 (en) | Methods and compositions for treatment of alzheimer's disease | |
| JP2019023195A (ja) | Ｌ−４−クロロキヌレニンの剤形及び治療的使用 | |
| KR20150038072A (ko) | 라퀴니모드와 팜프리딘의 병용물에 의한 다발성 경화증의 치료 | |
| KR20120050512A (ko) | 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료 | |
| US10357492B2 (en) | Levosimendan for use in the treatment of motor neuron diseases (E.G. ALS) | |
| JP6420923B1 (ja) | 医薬 | |
| AU2013301125B2 (en) | A3 adenosine receptor ligands for use in treatment of a sexual dysfunction | |
| JP2020525548A (ja) | 炎症反応を伴う疼痛状態における鎮痛のための末梢限局的二重作用性κおよびδオピオイドアゴニスト | |
| MX2014000455A (es) | Terapia de combinacion para esclerosis lateral amiotrofica. | |
| NZ619924B2 (en) | Combination als therapy | |
| HK1248552B (en) | Method of treatment with tradipitant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |